Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
4.980
+0.320 (6.87%)
At close: Dec 20, 2024, 4:00 PM
5.16
+0.18 (3.61%)
After-hours: Dec 20, 2024, 7:59 PM EST

Company Description

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.

It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada.

Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Vivos Therapeutics, Inc.
Vivos Therapeutics logo
Country United States
Founded 2016
IPO Date Dec 11, 2020
Industry Medical Devices
Sector Healthcare
Employees 123
CEO R. Huntsman

Contact Details

Address:
7921 Southpark Plaza, Suite 210
Littleton, Colorado 80120
United States
Phone 844 672 4357
Website vivos.com

Stock Details

Ticker Symbol VVOS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0001716166
CUSIP Number 92859E108
ISIN Number US92859E2072
Employer ID 81-3224056
SIC Code 3841

Key Executives

Name Position
R. Kirk Huntsman Co-Founder, Chairman of the Board and Chief Executive Officer
Bradford K. Amman Chief Financial Officer, Treasurer and Secretary
Todd Huntsman Co-Founder and Senior Vice President of Product and Technology
RaeAnn Byrnes Co-Founder and Senior Vice President of Events and Clinical Advisory Services
Susan McCullough Co-Founder and Executive Vice President of Operations
Nicholas M. DeGennaro Senior Vice President of Medical Integration Division
Ruth Hembree Senior Vice President of Practice Services
Stephanie Huebner Senior Vice President of Dental Service Integration
John Ballard Senior Vice President of Technology

Latest SEC Filings

Date Type Title
Dec 20, 2024 SCHEDULE 13G Filing
Nov 27, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 7, 2024 DEF 14A Other definitive proxy statements
Sep 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 20, 2024 8-K Current Report